Emerging therapeutic targets for synovial sarcoma

Emanuela Palmerini, Anna Paioli, Stefano Ferrari

Research output: Contribution to journalArticle

Abstract

Synovial sarcoma is part of soft tissue sarcomas, an uncommon group of malignant tumors of mesenchymal origin. Unfortunately, a very limited number of useful drugs are active for most advanced synovial sarcoma. These tumors showed VEGF expression, and elevated serum VEGF levels correlate with higher histologic tumor grade. Inhibition of VEGFR was associated with tumor activity in preclinical models of synovial sarcoma and drugs such as sorafenib, pazopanib and bevacizumab have been employed in synovial sarcoma in monotherapy and in combination with chemotherapy. Other targets such as EGFR, HER2, IGFR-1R and mTOR have been exploited, but their inhibition by drugs such as gefitinib, trastuzumab, figitumumab, and temsirolimus, has not resulted in meaningful activity. Newer approaches include CXCR4 inhibition, immune-based therapies (NY-ESO-1), targeting epigenetic misregulation with HDAC inhibitors and targeting developmental pathways such Notch and Hedgehog. This review will summarize achievements and pitfalls of drugs against emerging therapeutic targets for synovial sarcoma.

Original languageEnglish
Pages (from-to)791-806
Number of pages16
JournalExpert Review of Anticancer Therapy
Volume14
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Synovial Sarcoma
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Therapeutics
Neoplasms
Histone Deacetylase Inhibitors
Combination Drug Therapy
Epigenomics
Sarcoma
Serum
Inhibition (Psychology)

Keywords

  • CXCR4
  • HDAC inhibitors
  • IGFR-1R
  • mTOR
  • Notch
  • NY-ESO-1
  • Soft tissue sarcoma
  • Synovial sarcoma
  • Therapeutic targets
  • VEGFR

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Emerging therapeutic targets for synovial sarcoma. / Palmerini, Emanuela; Paioli, Anna; Ferrari, Stefano.

In: Expert Review of Anticancer Therapy, Vol. 14, No. 7, 2014, p. 791-806.

Research output: Contribution to journalArticle

Palmerini, Emanuela ; Paioli, Anna ; Ferrari, Stefano. / Emerging therapeutic targets for synovial sarcoma. In: Expert Review of Anticancer Therapy. 2014 ; Vol. 14, No. 7. pp. 791-806.
@article{2cb508b982804ed09dd6d2e75c4bbdea,
title = "Emerging therapeutic targets for synovial sarcoma",
abstract = "Synovial sarcoma is part of soft tissue sarcomas, an uncommon group of malignant tumors of mesenchymal origin. Unfortunately, a very limited number of useful drugs are active for most advanced synovial sarcoma. These tumors showed VEGF expression, and elevated serum VEGF levels correlate with higher histologic tumor grade. Inhibition of VEGFR was associated with tumor activity in preclinical models of synovial sarcoma and drugs such as sorafenib, pazopanib and bevacizumab have been employed in synovial sarcoma in monotherapy and in combination with chemotherapy. Other targets such as EGFR, HER2, IGFR-1R and mTOR have been exploited, but their inhibition by drugs such as gefitinib, trastuzumab, figitumumab, and temsirolimus, has not resulted in meaningful activity. Newer approaches include CXCR4 inhibition, immune-based therapies (NY-ESO-1), targeting epigenetic misregulation with HDAC inhibitors and targeting developmental pathways such Notch and Hedgehog. This review will summarize achievements and pitfalls of drugs against emerging therapeutic targets for synovial sarcoma.",
keywords = "CXCR4, HDAC inhibitors, IGFR-1R, mTOR, Notch, NY-ESO-1, Soft tissue sarcoma, Synovial sarcoma, Therapeutic targets, VEGFR",
author = "Emanuela Palmerini and Anna Paioli and Stefano Ferrari",
year = "2014",
doi = "10.1586/14737140.2014.901155",
language = "English",
volume = "14",
pages = "791--806",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Emerging therapeutic targets for synovial sarcoma

AU - Palmerini, Emanuela

AU - Paioli, Anna

AU - Ferrari, Stefano

PY - 2014

Y1 - 2014

N2 - Synovial sarcoma is part of soft tissue sarcomas, an uncommon group of malignant tumors of mesenchymal origin. Unfortunately, a very limited number of useful drugs are active for most advanced synovial sarcoma. These tumors showed VEGF expression, and elevated serum VEGF levels correlate with higher histologic tumor grade. Inhibition of VEGFR was associated with tumor activity in preclinical models of synovial sarcoma and drugs such as sorafenib, pazopanib and bevacizumab have been employed in synovial sarcoma in monotherapy and in combination with chemotherapy. Other targets such as EGFR, HER2, IGFR-1R and mTOR have been exploited, but their inhibition by drugs such as gefitinib, trastuzumab, figitumumab, and temsirolimus, has not resulted in meaningful activity. Newer approaches include CXCR4 inhibition, immune-based therapies (NY-ESO-1), targeting epigenetic misregulation with HDAC inhibitors and targeting developmental pathways such Notch and Hedgehog. This review will summarize achievements and pitfalls of drugs against emerging therapeutic targets for synovial sarcoma.

AB - Synovial sarcoma is part of soft tissue sarcomas, an uncommon group of malignant tumors of mesenchymal origin. Unfortunately, a very limited number of useful drugs are active for most advanced synovial sarcoma. These tumors showed VEGF expression, and elevated serum VEGF levels correlate with higher histologic tumor grade. Inhibition of VEGFR was associated with tumor activity in preclinical models of synovial sarcoma and drugs such as sorafenib, pazopanib and bevacizumab have been employed in synovial sarcoma in monotherapy and in combination with chemotherapy. Other targets such as EGFR, HER2, IGFR-1R and mTOR have been exploited, but their inhibition by drugs such as gefitinib, trastuzumab, figitumumab, and temsirolimus, has not resulted in meaningful activity. Newer approaches include CXCR4 inhibition, immune-based therapies (NY-ESO-1), targeting epigenetic misregulation with HDAC inhibitors and targeting developmental pathways such Notch and Hedgehog. This review will summarize achievements and pitfalls of drugs against emerging therapeutic targets for synovial sarcoma.

KW - CXCR4

KW - HDAC inhibitors

KW - IGFR-1R

KW - mTOR

KW - Notch

KW - NY-ESO-1

KW - Soft tissue sarcoma

KW - Synovial sarcoma

KW - Therapeutic targets

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=84903135832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903135832&partnerID=8YFLogxK

U2 - 10.1586/14737140.2014.901155

DO - 10.1586/14737140.2014.901155

M3 - Article

C2 - 24661286

AN - SCOPUS:84903135832

VL - 14

SP - 791

EP - 806

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 7

ER -